Literature DB >> 1997506

Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy.

A H Lockwood1, E W Yap, W H Wong.   

Abstract

Cerebral ammonia metabolism was studied in five control subjects and five patients with severe liver disease exhibiting minimal hepatic encephalopathy. The arterial ammonia concentration in the control subjects was 30 +/- 7 mumol/L (mean +/- SD) and 55 +/- 13 mumol/L in the patients (p less than 0.01). In the normal subjects, the whole-brain values for cerebral blood flow, cerebral metabolic rate for ammonia, and the permeability-surface area product for ammonia were 0.58 +/- 0.12 ml g-1 min-1 0.35 +/- 0.15 mumol 100 g-1 min-1, and 0.13 +/- 0.03 ml g-1 min-1, respectively. In the patients, the respective values were 0.46 +/- 0.16 ml g-1 min-1 (not different from control), 0.91 +/- 0.36 mumol 100 g-1 min-1 (p less than 0.025), and 0.22 +/- 0.07 ml g-1 min-1 (p less than 0.05). The increased permeability-surface area product of the blood-brain barrier permits ammonia to diffuse across the blood-brain barrier into the brain more freely than normal. This may cause ammonia-induced encephalopathy even though arterial ammonia levels are normal or near normal and explain the emergence of toxin hypersensitivity as liver disease progresses. Greater emphasis on early detection of encephalopathy and aggressive treatment of minimal hyperammonemia may retard the development of ammonia-induced complications of severe liver disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997506     DOI: 10.1038/jcbfm.1991.67

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  96 in total

Review 1.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 3.  Hepatic encephalopathy as a complication of liver disease.

Authors:  S vom Dahl; G Kircheis; D Häussinger
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 4.  Positron emission tomography in the study of hepatic encephalopathy.

Authors:  Alan H Lockwood
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 5.  Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy.

Authors:  Laurent Spahr; Pierre R Burkhard; Hannelore Grötzsch; Antoine Hadengue
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 6.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 7.  The basal ganglia and portal-systemic encephalopathy.

Authors:  K Weissenborn; H Kolbe
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 8.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

Authors:  Amit S Seyan; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 9.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

Review 10.  Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2015-11-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.